Avidity Biosciences is pioneering a new class of oligonucleotide-based therapies to address the unmet needs of the rare disease community.
Location: United States, California, La Jolla
Employees: 51-200
Total raised: $301M
Founded date: 2012
Investors 7
Funding Rounds 4
| Date | Series | Amount | Investors |
| 08.06.2020 | IPO | $150M | - |
| 13.11.2019 | Series C | $100M | - |
| 22.04.2019 | - | $35M | - |
| 05.01.2017 | Series B | $16M | - |
Mentions in press and media 15
| Date | Title | Description |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 27.07.2024 | The Future of Brain Health: Innovations and Leadership in Alzheimer's and Multiple Sclerosis Treatments | In the ever-evolving landscape of biotechnology, two companies are making waves in the treatment of chronic neurological diseases: Immunic, Inc. and Neurophet. Both are leveraging advanced technologies and seasoned leadership to tackle the ... |
| 24.07.2024 | Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec | – Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevu... |
| 08.01.2021 | Avidity Biosciences Announces 2021 Pipeline Updates and Research Collaboration with MyoKardia | |
| 08.06.2020 | Muscle disorder biotech Avidity Biosciences sets terms for $150 million IPO | - |
| 26.05.2020 | Biotech Muscle disorder biotech Avidity aims for the clinic with $100M IPO | - |
| 13.11.2019 | Avidity Biosciences has raised a $100M Series C to work on their preclinical programs for muscle disorders and other serious diseases. | - |
| 13.11.2019 | Avidity Biosciences Completes $100 Million Series C Financing | LA JOLLA, Calif.--(BUSINESS WIRE)--Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs) for the treatment of rare muscle disorders and other serious diseases, announced the completion of a $100 ... |
| 13.11.2019 | Avidity Biosciences Completes $100 Million Series C Financing | JOLLA, Calif.--(BUSINESS WIRE)--Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs™) for the treatment of rare muscle disorders and other serious diseases, announced the completion of a $100 mi... |
| 22.04.2019 | Daily funding roundup - April 22nd, 2019 | Novo Labs raised $2M; Driveroo secured $3.1M; Nabis landed $4M; Bridge Connector closed $20M Novo Labs: Novo Labs is a provider of conversational artificial intelligence services for large restaurant chains. Novo Labs has raised $2 million ... |
Show more